Nivolumab
Phase 2Active 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Bronchial Dysplasia
Conditions
Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer, History of Head and Neck Cancer
Trial Timeline
Jan 30, 2019 → Dec 31, 2026
NCT ID
NCT03347838About Nivolumab
Nivolumab is a phase 2 stage product being developed by Bristol Myers Squibb for Bronchial Dysplasia. The current trial status is active. This product is registered under clinical trial identifier NCT03347838. Target conditions include Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03126643 | Pre-clinical | Completed |
| NCT02475382 | Pre-clinical | Completed |
| NCT06523621 | Phase 2 | Recruiting |
| NCT06499298 | Pre-clinical | Completed |
| NCT06735781 | Pre-clinical | Completed |
| NCT06421311 | Pre-clinical | Terminated |
| NCT06452329 | Pre-clinical | Completed |
| NCT06003075 | Phase 2 | Terminated |
| NCT06361576 | Pre-clinical | Completed |
| NCT06361563 | Pre-clinical | Completed |
| NCT05068609 | Pre-clinical | Completed |
| NCT04936399 | Pre-clinical | Completed |
| NCT04205409 | Phase 2 | Active |
| NCT04401774 | Phase 2 | Completed |
| NCT04361058 | Phase 1 | Withdrawn |
| NCT04022980 | Phase 1 | Completed |
| NCT04019964 | Phase 2 | Completed |
| NCT04146324 | Pre-clinical | Completed |
| NCT04099251 | Phase 3 | Active |
| NCT03981146 | Phase 2 | Active |
Competing Products
20 competing products in Bronchial Dysplasia